A2P2™
Product-lifetime evidence, built from the material—not an assumption.
A2P2 is the patented enterprise framework and live platform for mechanism-driven accelerated ageing. It gives R&D, quality and regulatory teams a faster, traceable route from material behaviour to a defensible lifetime decision.
EXPERIENCE A2P2 DISCUSS ENTERPRISE LICENSING
337 → 71 DAYS
Bioreactor stability programme
£40 MILLION
Avoided waste associated with an adhesive shelf-life extension
8 YEARS
Prediction compared with continuous field service
A live platform for lifetime decisions
A2P2 brings experimental evidence, material-specific calculations, study design and decision records into one governed environment. The protected platform supports mechanism-specific workflows across creep, hydrolysis, oxidation, spectroscopy, thermal analysis and device-level Q₁₀ analysis.
From material behaviour to a defensible decision.
1 · Define the system
Materials, interfaces, processing, sterilisation and the intended lifetime claim.
2 · Identify the governing behaviour
Select the mechanism and experimental pathway that describe the product actually manufactured.
3 · Calculate and verify
Determine the acceleration factor, study duration, temperature domain and verification plan.
4 · Create the decision record
Connect source data, calculations, acceptance criteria and limitations for review.
Designed for enterprise adoption
A2P2 is not a one-off test. An implementation combines an annual framework and platform licence, a foundational programme around the organisation’s lead system, method transfer, laboratory implementation, team training and defined scientific governance.
Standards and regulatory pathway
A2P2 is being developed alongside active standards and regulatory work—not presented as an already mandated method. Dr Nazli Gulsine Ozdemir is the UK proposer for the ASTM F1980 revision work and is developing ASTM WK100588 on experimental Q₁₀ determination. She also contributes as a UK expert within ISO/TC 194/WG 1. A2P2 has been submitted to the FDA Medical Device Development Tools programme.
The result is an internal capability that can evolve with the evidence and the standards landscape.
EXPLORE THE PUBLIC DEMONSTRATION START A LICENSING DISCUSSION
Some of our partners
